You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HR-positive

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed Trial in Hangzhou (dalpiciclib;

Recruiting
  • Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed
  • dalpiciclib; fluvestrant; compound gossypol acetate tablets
  • Hangzhou, Zhejiang, China
    zhejiangCH
Nov 9, 2023

HER2 Low Breast Carcinoma Trial (SHR-A1811 for injection)

Not yet recruiting
  • HER2 Low Breast Carcinoma
  • SHR-A1811 for injection
  • (no location specified)
Jun 12, 2023

Breast Cancer Trial in Tianjin (Dalcelli?Exemestane?Gosserine, Docetaxel for injection?Epirubicin HCl for

Recruiting
  • Breast Cancer
  • Tianjin, Tianjin, China
    Jie Ge
Aug 20, 2023

Breast Cancer Trial in Chengdu (Dalpiciclib combined with Letrozole)

Not yet recruiting
  • Breast Cancer
  • Dalpiciclib combined with Letrozole
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Aug 3, 2023

Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma Trial in Guangzhou (Pyrotinib,

Not yet recruiting
  • Breast Cancer Invasive
  • +3 more
  • Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
  • Placebo, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
  • Guangzhou, Guangdong, China
    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Nov 17, 2023

Breast Cancer Trial in Shanghai (Dalpiciclib, Fulvestrant, Pertuzumab)

Active, not recruiting
  • Breast Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Oct 10, 2022

Breast Cancer Trial (Giredestrant, Abemaciclib, Inavolisib)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
Feb 1, 2023

Breast Tumor Female Trial in Beijing (CDK4/6 inhibitor (Qilu),Trastuzumab (Hanquyou))

Recruiting
  • Breast Neoplasm Female
  • CDK4/6 inhibitor (Qilu),Trastuzumab (Hanquyou)
  • Beijing, Beijing, China
  • +1 more
Jul 31, 2023

Breast Cancer Trial in Nanjing (Neoadjuvant therapy: TCbHPy, Neoadjuvant therapy: TCbHP)

Not yet recruiting
  • Breast Cancer
  • Neoadjuvant therapy: TCbHPy
  • Neoadjuvant therapy: TCbHP
  • Nanjing, China
    the First Affiliated Hospital of Nanjing Medical University
Jul 4, 2022

HR Positive HER2 Negative Advanced Breast Cancer Trial in Tianjin (Chidamide)

Recruiting
  • HR Positive HER2 Negative Advanced Breast Cancer
  • Tianjin, China
    天津市肿瘤医院
May 26, 2023

Solid Tumor Trial (Dalpiciclib)

Not yet recruiting
  • Solid Tumor
  • (no location specified)
Aug 22, 2022

Breast Cancer Trial in Guangzhou (Tucidinostat, Capecitabine, Endocrine Therapy)

Recruiting
  • Breast Cancer
  • Guangzhou, Gangdong, China
    Shusen Wang
Nov 1, 2022

Advanced Breast Cancer Trial in Thalassery (Alpelisib, Fulvestrant)

Recruiting
  • Advanced Breast Cancer
  • Thalassery, Kerala, India
    Novartis Investigative Site
Nov 21, 2022

Breast Cancer Trial in Zhengzhou (Capecitabine+endocrine therapy, Placebo+endocrine therapy)

Recruiting
  • Breast Cancer
  • Capecitabine+endocrine therapy
  • Placebo+endocrine therapy
  • Zhengzhou, Henan, China
    Henan cancer hospital
Nov 19, 2022

Breast Cancer, Breast Cancer Female Trial in China (surufatinib + fulvestrant + chidamide)

Not yet recruiting
  • Breast Cancer
  • Breast Cancer Female
  • surufatinib + fulvestrant + chidamide
  • Anyang, China
  • +4 more
Jul 18, 2022

Breast Cancer, Metastatic Cancer Trial (SHR-1316, SHR6390, Nab paclitaxel)

Not yet recruiting
  • Breast Cancer
  • Metastatic Cancer
  • (no location specified)
Jan 11, 2022

Breast Cancer, Chemotherapeutic Toxicity Trial in Hanzhou (Liposomal doxorubicin + Cyclophosphamide vs Docetaxel +

Recruiting
  • Breast Cancer
  • Chemotherapeutic Toxicity
  • Liposomal doxorubicin + Cyclophosphamide vs Docetaxel + Cyclophosphamide
  • Hanzhou, Zhejing, China
    Second Affiliated Hospital, School of Medicine, Zhejiang Univers
Apr 7, 2022

Solid Tumor, Adult Trial (EOC202, albumin-bound paclitaxel)

Not yet recruiting
  • Solid Tumor, Adult
  • EOC202
  • albumin-bound paclitaxel
  • (no location specified)
Apr 7, 2022

Advanced Breast Cancer Trial in Beijing (Dalpiciclib in combination with endocrine therapy by Physicians choice)

Not yet recruiting
  • Advanced Breast Cancer
  • Dalpiciclib in combination with endocrine therapy by Physicians choice
  • Beijing, Beijing, China
    Cancer Hospital, Chinese Academy of Medical Sciences
Jun 19, 2022

HR+, HER2-, Advanced Breast Cancer Trial (alpelisib)

Available
  • HR+, HER2-, Advanced Breast Cancer
  • (no location specified)
Jul 5, 2022

Metastatic Breast Cancer, Advanced Breast Cancer, HR-positive Breast Cancer Trial (OP-1250, Ribociclib, Alpelisib)

Not yet recruiting
  • Metastatic Breast Cancer
  • +3 more
  • (no location specified)
Aug 18, 2022

HER2-positive Breast Cancer Trial (Inavolisib, PHESGO, Endocrine therapy)

Not yet recruiting
  • HER2-positive Breast Cancer
  • (no location specified)
Mar 23, 2022

Patterns of Advanced Breast Cancer in Poland in Real-world Data

Recruiting
  • Breast Neoplasms
    • Warsaw, Poland
      Pfizer Polska
    Jul 26, 2022

    Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer Trial in Ocala (Samuraciclib, Fulvestrant)

    Recruiting
    • Metastatic Breast Cancer
    • +2 more
    • Ocala, Florida
      Ocala Oncology Center PL DBA Florida Cancer Affiliates
    Jul 19, 2023

    Advanced HR+ HER2 Negative Breast Carcinoma Trial in Tianjin (Enituzumab injection+Abesili tablets+Anastrozole tablets)

    Recruiting
    • Advanced HR+ HER2 Negative Breast Carcinoma
    • Enituzumab injection+Abesili tablets+Anastrozole tablets
    • Tianjin, China
      Tianjin Cancer Hospital
    Apr 6, 2022